Qingfei Liyan Reduce Occupational Injury of Dust
Release time:
2020-07-07
The current situation of occupational hazards in China is very serious. According to incomplete statistics from the Ministry of Health, in recent years, the number of workers suffering from occupational diseases, death, disability and incapacity due to dust, radioactive substances and other toxic and harmful operations has been increasing. The scope of dust occupational injury is the widest, accounting for more than 80% of all occupational diseases. The main occupational hazards caused by dust are pneumoconiosis, which is a systemic disease mainly caused by diffuse fibrosis of lung tissue caused by long-term inhalation of productive dust in production activities. Pneumoconiosis early generally no clinical symptoms, but some patients have chest tightness, cough, expectoration. As the above symptoms worsen, there will be concurrent signs such as tightness of the air, asthma, and dyspnea. The late stage may be complicated by emphysema and pulmonary heart disease.
In addition to the attention of the enterprise and the prevention of the working environment, what preventive measures can the individual as an employee take?
Dust has the greatest impact on the respiratory system, which has become the consensus of most people. The respiratory system has the most frequent contact with the external environment, and the contact area is large. Hundreds of atmospheric particles can directly enter and adhere to the upper and lower respiratory tract and lung lobes of the human body, and most of them will be inhaled by the human body. Therefore, the first step to reduce damage, enhance the self-cleaning power of the lungs, and eat more foods and teas that clear the lungs and moisten the lungs.
The human body itself contains the independent ability to maintain health. A healthy body will burst out the potential to resist danger when facing external challenges. However, a large area, continuous dust, accumulated over time, the human body's independent health ability is weakened in the face of pollution, which has caused many diseases. Therefore, only by improving the ability of the autoimmune system can the toxins that are inevitably inhaled into the body be discharged from the body as soon as possible; in the face of inhaled dust, our most realistic way is to improve our own independent health ability and resist environmental damage.
boiling jade Jing teabag. Zhejiang Jianfeng Health Technology Co., Ltd., in conjunction with the Occupational Disease Prevention and Control Institute of Jiangsu Provincial Center for Disease Control and Prevention, adopts modern cell screening technology to refine and improve the formula, combined with the use of modern preparation technology to concentrate the active ingredients, with tea, made of clear efficacy, quality controllable tea bags.
Boiling Yujing Tea has the effects of clearing the lung and improving the pharynx, reducing lung occupational diseases and smog injuries, and has obvious effects on pharynx itching, dry pharynx and lung injuries caused by various dust and particles. It is especially suitable for industries with serious dust injuries such as cement, coal mines, electric welding, and groups exposed to dust all the year round, such as sanitation workers, traffic police, etc.
Boiling Yujing teabag, sugar-free, low-calorie, easy to brew and drink, is to protect you and the people you love to achieve independent health, lung detoxification, improve immunity, prevent dust damage necessary to share.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page